Cart
sales@molnova.com
MD 39-AM
CAS No. 72564-74-0
MD 39-AM( MD-39-AM | MD 39 AM | MD39AM )
Catalog No. M17581 CAS No. 72564-74-0
Anticytokinin activity was evaluated by 50% of the callus growth on the medium with kinetin but without anti-cytokinin
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 82 | In Stock |
|
| 2MG | 36 | In Stock |
|
| 5MG | 55 | In Stock |
|
| 10MG | 86 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMD 39-AM
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnticytokinin activity was evaluated by 50% of the callus growth on the medium with kinetin but without anti-cytokinin
-
DescriptionMD-39-AM is a diuretic agent, impling an increase in the Na+ excretion and showing antihypertensive effect.
-
In Vitro——
-
In Vivo——
-
SynonymsMD-39-AM | MD 39 AM | MD39AM
-
PathwayCell Cycle/DNA Damage
-
TargetROCK
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number72564-74-0
-
Formula Weight268.34
-
Molecular FormulaC14H12N4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCSc1nc2c(cccn2)c(n1)Nc1ccccc1
-
Chemical Name2-Methylsulfanyl-N-phenylpyrido[2,3-d]pyrimidin-4-amine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pérez MJ, et al. Preliminary pharmacokinetics of a new pyridopyrimidine derivative. Arzneimittelforschung. 1991 Jun;41(6):640-4.
molnova catalog
related products
-
RKI-1447
RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.
-
Azaindole 1
Azaindole 1 is a selective and ATP-competitive ROCK inhibitor with IC50 of 0.6 and 1.1?nM for human ROCK-1 and ROCK-2.
-
Rho-Kinase-IN-1
Rho-Kinase-IN-1 is a inhibitor of Rho kinase (ROCK) with Ki values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively.
